Somerville Kurt F Sells 400 Shares of Pfizer Inc. (NYSE:PFE)

Somerville Kurt F lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 27,772 shares of the biopharmaceutical company’s stock after selling 400 shares during the period. Somerville Kurt F’s holdings in Pfizer were worth $998,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Weybosset Research & Management LLC grew its position in Pfizer by 2.0% during the second quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 250 shares during the period. Financial Gravity Wealth Inc. grew its position in Pfizer by 33.2% during the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 257 shares during the period. Intl Fcstone Inc. grew its position in Pfizer by 2.4% during the second quarter. Intl Fcstone Inc. now owns 11,140 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 261 shares during the period. Lee Financial Co grew its position in Pfizer by 6.2% during the second quarter. Lee Financial Co now owns 4,569 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 265 shares during the period. Finally, Sheets Smith Wealth Management grew its position in Pfizer by 0.6% during the third quarter. Sheets Smith Wealth Management now owns 47,993 shares of the biopharmaceutical company’s stock valued at $1,724,000 after buying an additional 272 shares during the period. Institutional investors own 71.51% of the company’s stock.

In other news, major shareholder Pfizer Inc purchased 50,000 shares of the stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, with a total value of $900,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Scott Gottlieb purchased 3,000 shares of the stock in a transaction dated Friday, August 23rd. The stock was purchased at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the acquisition, the director now owns 3,000 shares of the company’s stock, valued at approximately $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is owned by company insiders.

Several equities analysts recently weighed in on the stock. ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. UBS Group restated a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. DZ Bank upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a research report on Wednesday, August 28th. Finally, Morgan Stanley cut their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 27th. Nine equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $44.02.

NYSE:PFE traded down $0.37 on Wednesday, reaching $36.60. 24,656,176 shares of the company’s stock were exchanged, compared to its average volume of 23,271,600. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.90 and a quick ratio of 0.68. The firm has a market cap of $205.04 billion, a price-to-earnings ratio of 12.20, a P/E/G ratio of 3.29 and a beta of 0.67. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $46.47. The stock has a fifty day simple moving average of $36.65 and a 200-day simple moving average of $39.21.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.13. The firm had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. The company’s quarterly revenue was down 4.6% on a year-over-year basis. During the same quarter last year, the business earned $0.78 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.36 per share. The ex-dividend date is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a yield of 3.93%. Pfizer’s dividend payout ratio is presently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: What are high-yield dividend stocks?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.